TRINAMIC
7.11.2016 16:32:35 CET | Business Wire | Press release
Trinamic Motion Control GmbH & Co. KG, a leading supplier of semiconductors, electronics and mechatronic solutions in the fields of motor and motion control, is proud to announce the arrival of a new family of high-performance semiconductor components for stepper motor control. The TMC2208-LA and TMC2224-LA are monolithic components with integrated circuit breakers for up to 1.2A RMS, and optimal power controllers for noiseless, sinusoidal control of the motor phases. Above all, both components were designed with the goal of easy application in mind. Trinamic will present the drives to the public at Electronica 2016, in Hall A4 at booth 513.
"Developers are under increasing pressure to shorten development cycles and bring new products on the market faster," explains Michael Randt, founder and CEO of Trinamic. "Our new family of drivers has been specially developed to help make the development process as short and as simple as possible."
Enhanced by the flexible microPlyer interpolater unit, the components offer a resolution of up to 256 microsteps-per-full-step to achieve perfect sinusoidal control - even with low-resolution motion controllers. Further development of Trinamic's stealthChop technology, which was introduced two years ago, has all but eliminated motor noise at low speeds, making the precise control of stepper motors not only possible, but affordable for application in environments that demand absolute silence, e.g. office buildings and residential areas.
Due to the immense popularity of stealthChop technology, the components have been designed for compatibility with existing 3D printer electronics. With stealthChop there is no need for costly redesign.
Both components feature a step/direction source for fully autonomous operation. Configuration is achieved via digital inputs.
The components will be available at a price of USD 1.22 at quantities of 1000 as a QFN28 (5x5) package in the first quarter of 2017. To accelerate the design process, Trinamic offers complete end-to-end evaluation kits. The development boards are open-source hardware and freely available for use as a reference design.
About Trinamic
Trinamic, headquartered in Hamburg, provides integrated circuits and motor control modules to customers worldwide. The company's application-driven approach and in-depth understanding of their customers' needs allow them to offer solutions which simplify and shorten the design phase, resulting in significant cost savings, decreased resource allocation and a reduced total cost of ownership. Trinamic's customers benefit from the company's rich expertise in motor physics and extensive portfolio of intellectual property (IP) acquired through many years of applied experience and success. Product development at Trinamic focuses entirely on miniaturizing form factor, increasing efficiency and maximizing the safety and reliability of their products and, thereby, the systems in which they're used.
The company is fully committed to providing energy efficient solutions. Industry-leading technologies such as Trinamic's patented coolStep™ products offer user-friendliness, precise stepper motor control and, above all, energy savings.
The Trinamic Motion Control Language (TMCL) facilitates the development of motor control applications, enabling shorter development cycles and rapid product release.
Over 20 years of experience and a traditional German ownership structure with private shareholders ensure the long-term availability of their products and components.
From the headquarters in Hamburg, Germany, Trinamic products are sold via a worldwide distribution network.
Printable graphics and an English-language version of this press release are available at:
http://www.trinamic.com/company/press/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005244/en/
Contact:
Trinamic
Jonas P. Proeger, +49 (0) 40 514 806-0
Marketing
Director
proeger@trinamic.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
